Steroid treatment for type of kidney disease associated with increased risk for serious infections


Among patients with IgA nephropathy and excess protein in their urine, treatment with pills of the steroid methylprednisolone was associated with an unexpectedly large increase in the risk of serious adverse events, primarily infections, according to a study. IgA nephropathy is a kidney disease that occurs when the antibody immunoglobulin A (IgA) lodges in the kidneys.

I’m Afraid of Blowing My Paycheck

Dear E. Jean: My new salary makes me nervous. It’s so much money, I’m scared that I’m going to end up blowing it. I’m afraid I’ll feel too comfortable spending it. How can I avoid losing my head? —Nervous Working Girl

Aw, Hell, Working: You should lose your head. A woman who doesn’t lose her head when she wins a big new salary is probably too dumb to receive it.

Advertisement – Continue Reading Below

I realize this is not the kind of advice any decent columnist would give an ambitious woman, but Auntie Eeee is not decent. After two or three days of blowing it, you must get serious, of course, and have yourself tied to the mast like Ulysses and sail by Bergdorf’s without going inside—but a new salary? It’s to be enjoyed, else why go to work?

Then sign up (it’s free) on Mint.com. You’ll be able to view your financial accounts via charts and graphs that will help you set a budget, track your spending, set goals, and organize an investment plan. I’m waiting for them to build a new feature where they make us all rich widows without having to marry anyone.

P.S. If you’re not down with the whole “Spend it! It’s good for you!” philosophy, just forward your salary to me at my mountain cabin, along with a certified check for $1,800. That’s my fee for splurging and enjoying your money.

This letter is from the E. Jean archive.

Study allays concerns over aspirin's safety for heart failure patients


A new study allays concerns among cardiologists that aspirin could increase the risk of hospitalization and death related to heart failure for patients with heart failure who take one of the first-line therapies: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).